The results from this decision analysis, based on probabilities of major events and associated utilization from an expert panel, suggest that divalproex sodium extended-release results in lower total costs than valproic acid in the treatment of bipolar disorder. Limitations of this study primarily involved the sources of data used in the model, including that derived from expert opinion.
No takes yet. Share an insight, caveat, or question.
Schumock et al. (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: